Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist

BACKGROUND: Experimental cancer vaccines are traditionally administered by injection in subcutaneous tissue or muscle, commonly with adjuvants that create chronic inflammatory depots. Injection of melanoma-derived peptides induces T cell responses; however, the depots that form following injection m...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Meneveau, Max O, Petroni, Gina R, Salerno, Elise P, Lynch, Kevin T, Smolkin, Mark, Woodson, Elizabeth, Chianese-Bullock, Kimberly A, Olson, Walter C, Deacon, Donna, Patterson, James W, Grosh, William W, Slingluff, Craig L
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2021
Pynciau:
Clinical/Translational Cancer Immunotherapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8154977/
https://ncbi.nlm.nih.gov/pubmed/34035112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002214
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg